Gerresheimer stock gains on Q1 revenue and cash flow
Published on 09/03/2026 at 07:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gerresheimer stock gained after the Germany-listed group (ISIN DE000A0LD6E6) closed at EUR 27.90 on September 2, 2026, up 1.90 percent on the day and 9.84 percent over five days. The move came as the latest Q1 2026 figures showed revenue of EUR 524 million, adjusted EBITDA of EUR 66 million and free cash flow of minus EUR 32 million.
Q1 numbers set the tone
According to Manufacturing Chemist, Q1 2026 revenue was EUR 524 million, compared with EUR 519 million in Q1 2025, while adjusted EBITDA fell to EUR 66 million from EUR 81 million. The adjusted EBITDA margin also slipped to 12.6 percent from 15.7 percent.
The same report said free cash flow improved to minus EUR 32 million from minus EUR 141 million a year earlier. That is a change of EUR 109 million, and it puts cash generation back at the center of the story for investors.
Cash and sales drive the debate
MarketScreener showed Gerresheimer at EUR 27.90 on Xetra on September 2, 2026, with a one-year range of EUR 14.83 to EUR 44.76 and year-to-date performance of 1.16 percent. The stock also traded above its five-day starting point of EUR 26.52 on August 27, 2026.
On the company side, the market is still weighing the 2026 guidance reset. Gerresheimer said in late June that it was targeting an adjusted EBITDA margin of 17 to 18 percent, down from 18 to 19 percent previously, and free cash flow of minus EUR 50 million to minus EUR 100 million.
Q1 2026 figures and guidance change
The latest report tied EUR 524 million in revenue, EUR 66 million in adjusted EBITDA and minus EUR 32 million in free cash flow to the ongoing portfolio shift.
Drug delivery stays central
Gerresheimer's Q1 split showed Containment and Delivery Systems at EUR 296 million in revenue, up from EUR 281 million in Q1 2025, while Primary Injectable Solutions reached EUR 101 million versus EUR 94 million a year earlier. Moulded Glass moved the other way, with revenue of EUR 144 million compared with EUR 160 million and adjusted EBITDA of EUR 6 million versus EUR 32 million.
For investors, that mix matters more than the headline group total. Growth is concentrated in drug delivery devices and syringe systems, while the glass business still drags on margin and earnings quality.
Xetra price stays in view
Gerresheimer AG is valued by the market at about EUR 963.7 million on Yahoo Finance and traded on Xetra under ticker GXI on September 2, 2026. The stock closed at EUR 27.90, with the last five sessions covering EUR 26.52 to EUR 28.12.
Gerresheimer AG at a glance
- Company: Gerresheimer AG
- ISIN: DE000A0LD6E6
- Ticker: GXI
- Trading venue: Xetra
- Price (as of September 2, 2026): EUR 27.90
- Market capitalization: EUR 963.7 million
- Sector / Industry: Medical Supplies
- Index membership: SDAX
- Next earnings date: October 14, 2026
Drug delivery is the product angle
The company pointed to Containment and Delivery Systems, Primary Injectable Solutions and drug delivery devices as the growth engines in Q1 2026. That is the part of the portfolio that now carries the strongest operating momentum, even as Moulded Glass remains under pressure.
Stock stays above 27 euros
Gerresheimer stock finished September 2, 2026 at EUR 27.90 on Xetra, after a 1.90 percent daily rise. The share also stood 1.16 percent higher for 2026 and 9.84 percent above its level five days earlier.
